drugset
drugset / Trial / NCT05200260

Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer

NCT05200260 ↗

Phase 2 Recruiting 220 enrolled Shanghai Gynecologic Oncology Group Fudan University · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

Optimal Timing of Surgery combined with Maintenance Therapy in the Front-line Treatment of Advanced Ovarian Cancer

Timeline

Start
2022-07-13
Primary completion
2027-06
Completion
2027-06

Drugs

EvaluationDrugModalityDoseRoute
Background Bevacizumab Monoclonal antibody 7.5 mg/kg Intravenous
Background Olaparib Small molecule 300 mg Oral

Indications

fallopian tube cancer ovarian cancer primary peritoneal carcinoma